Beruzatatug pelitecan - BioNTech/MediLink Therapeutics
Alternative Names: BNT-326; YL-202Latest Information Update: 02 Aug 2026
At a glance
- Originator MediLink Therapeutics
- Developer BioNTech; MediLink Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer; Non-small cell lung cancer
- Phase II Breast cancer; Solid tumours
Most Recent Events
- 22 Jul 2026 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in Turkey (IV) (NCT07070232)
- 22 Jul 2026 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Monotherapy) in Turkey (IV) (NCT07070232)
- 18 Mar 2026 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in China (IV) (NCT07416994)